Infant Bacterial Therapeutics AB (publ) (IBT-B) - Total Liabilities
Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has total liabilities worth Skr53.87 Million SEK (≈ $5.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Infant Bacterial Therapeutics AB (publ) - Total Liabilities Trend (2013–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See Infant Bacterial Therapeutics AB (publ) short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Infant Bacterial Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KAISER REEF LTD.
F:7YR
|
Germany | €6.14 Million |
|
OSE Pharma SA
PA:OSE
|
France | €53.58 Million |
|
Highlight Event Entertainment
SW:HLEE
|
Switzerland | CHF609.16 Million |
|
Transart Graphics Co Ltd
TW:8481
|
Taiwan | NT$212.56 Million |
|
GlycoNex
TWO:4168
|
Taiwan | NT$542.22 Million |
|
Delta Djakarta Tbk
JK:DLTA
|
Indonesia | Rp285.36 Billion |
|
Lion Selection Group Ltd
AU:LSX
|
Australia | AU$11.45 Million |
|
Imaflex Inc
V:IFX
|
Canada | CA$25.95 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Infant Bacterial Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IBT-B company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Infant Bacterial Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Infant Bacterial Therapeutics AB (publ) (2013–2024)
The table below shows the annual total liabilities of Infant Bacterial Therapeutics AB (publ) from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr69.30 Million ≈ $7.46 Million |
+50.07% |
| 2023-12-31 | Skr46.18 Million ≈ $4.97 Million |
+157.80% |
| 2022-12-31 | Skr17.91 Million ≈ $1.93 Million |
+35.46% |
| 2021-12-31 | Skr13.22 Million ≈ $1.42 Million |
+30.11% |
| 2020-12-31 | Skr10.16 Million ≈ $1.09 Million |
+29.05% |
| 2019-12-31 | Skr7.88 Million ≈ $847.58K |
+18.36% |
| 2018-12-31 | Skr6.65 Million ≈ $716.08K |
+0.02% |
| 2017-12-31 | Skr6.65 Million ≈ $715.97K |
+36.25% |
| 2016-12-31 | Skr4.88 Million ≈ $525.49K |
-36.86% |
| 2015-12-31 | Skr7.73 Million ≈ $832.30K |
+120.59% |
| 2014-12-31 | Skr3.51 Million ≈ $377.30K |
+1356.61% |
| 2013-12-31 | Skr240.70K ≈ $25.90K |
-- |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more